Evidence map›Paper›PMID 37468684›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2023

Treatment Burden on Once-Weekly Omarigliptin Versus Daily Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes: Randomized Controlled Trial (ONWARD-DPP4 Study).

Hitoshi Ishii, Nozomu Kamei, Dai Shimono, Tetsuji Niiya, Takahiro Tosaki, Toru Kitazawa, Daisuke Suzuki, Yutaka Wakasa, Hiroaki Seino, Mariko Oishi and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 2 pooled it
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 syntheses or guidelines pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Hitoshi IshiiDepartment of Doctor-Patient Relationships, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8521, Japan. hit3910@gmail.com.ORCID http://orcid.org/0000-0002-6214-0557
Nozomu KameiDepartment of Endocrinology and Metabolism, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima, Hiroshima, Japan.
Dai ShimonoFutata Tetsuhiro Clinic, Fukuoka, Fukuoka, Japan.
Tetsuji NiiyaMikannohana Clinic Diabetes, Endocrinology and Metabolism, Matsuyama, Ehime, Japan.
Takahiro TosakiTDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology, Nagoya, Aichi, Japan.
Toru KitazawaInternal Medicine and Cardiovascular Murai Clinic, Bunkyo-ku, Tokyo, Japan.
Daisuke SuzukiSTOP DM Suzuki Diabetes Clinic, Atsugi, Kanagawa, Japan.
Yutaka WakasaWakasa Medical Clinic, Kanazawa, Ishikawa, Japan.
Hiroaki SeinoSeino Internal Medical Clinic, Koriyama, Fukushima, Japan.
Mariko OishiOishi Clinic, Kyoto, Kyoto, Japan.
Hiroshi OhashiOyama East Clinic, Oyama, Tochigi, Japan.
Kenshi HigamiHigami Clinic of Rheumatology and Diabetology, Kashihara, Nara, Japan.
Hiroaki AkaiDivision of Metabolism and Diabetes, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Miyagi, Japan.
ONWARD-DPP4 study investigators
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPKanazawa Medical Center · JPNara Medical University · JPOno Clinic · JPSuzugamine Women's College · JPSuzuki (Japan) · JPThe Cancer Institute Hospital · JPTohoku Medical and Pharmaceutical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPreference for quality of life is important in deciding the treatment strategy for patients with type 2 diabetes mellitus. This study aimed to assess the effect of omarigliptin on patients' psychological attitudes and responses compared with daily dipeptidyl peptidase-4 inhibitors (DPP4is) by measuring the burden of pharmacotherapy using the Diabetic Treatment Burden Questionnaire (DTBQ).

methodsPatients with type 2 diabetes mellitus who were taking daily DPP-4is were enrolled and randomized to a group that switched to omarigliptin or a group that continued daily DPP4is and were monitored for 12 weeks. The primary endpoint was the change in the DTBQ score from baseline to week 12. The secondary endpoints included changes in blood test results, medication preferences and medication adherence.

resultsThe DTBQ total score significantly decreased from baseline to week 12 in both groups; however, no significant intergroup differences were observed. The DTBQ subscale, implementation and flexibility burden scores significantly decreased in the group that switched to omarigliptin, although no significant intergroup difference in the change was observed. DTBQ scores and medication preferences were associated with improvements in the DTBQ scores.

conclusionAlthough this study failed to demonstrate the improvement of DTBQ total score by switching from daily DPP4is to omarigliptin compared with continuing the daily DPP4is, the DTBQ subscale score implementation and flexibility burden score were significantly improved only in the group that switched to omarigliptin, suggesting the possibility of switching from daily DPP4is to omarigliptin to decrease the patients' medication burden.

trial registrationjRCTs031200437.

Indexed as

Dipeptidyl peptidase-4 inhibitorOmarigliptinQuality of lifeTreatment burdenType 2 diabetes mellitus

Identifiers

PMID37468684
PMCPMC10499707
OpenAlexW4384820552

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.